Search results: (10000)
News Options for Reducing or Discontinuing TPO-RA Therapy in ITP Patients − Expert Consensus
There are currently no clear recommendations regarding dose reduction or discontinuation of thrombopoietin receptor agonists (TPO-RA) in patients with immune thrombocytopenia (ITP). A consensus by British authors offers insights into current clinical practice and the related issues.
News Current Findings on Progressive Fibrosis in Interstitial Lung Disease
Leading pulmonologists around the world recently published the first of a series of three review articles on interstitial lung disease in The Lancet Respiratory Medicine journal. This article focuses on histopathology and the relationship of this disease with lung fibrosis. It also addresses the question of whether progressive lung tissue fibrosis pertains only to usual interstitial pneumonia.
News New ESMO Recommendations for Investigating Circulating Tumor DNA
Liquid biopsy has been discussed in oncology for several decades. As we move from conference abstracts to its real-world application in clinical practice, the new recommendations of the European Society for Medical Oncology (ESMO) describe the examination of circulating tumor DNA from peripheral blood.
News Finding Balance Between Intracranial Efficacy and Adverse Effects of ALK Kinase Inhibition
More than 7 years – that is the current median survival of patients with non-small cell lung cancer (NSCLC) with a mutation in the anaplastic lymphoma kinase (ALK) gene who are receiving targeted therapy. Therefore, the quality of life of patients on treatment and the search for a balance between its antitumor efficacy and adverse effects (AEs) is becoming the focus of clinical research. Recently, lorlatinib has been discussed in this context.
News Lorlatinib as an Alternative to CNS Radiotherapy in Patients with NSCLC − Case Studies
Two remarkable case studies from authors at the Netherlands Cancer Institute Antoni van Leeuwenhoek in Amsterdam present patients with advanced NSCLC with metastatic CNS involvement. Treatment with crizotinib led to good control of pulmonary involvement but did not affect metastatic CNS involvement. The introduction of lorlatinib subsequently led to rapid improvement in neurological symptoms, which was also confirmed by CNS imaging.
News Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice
Interesting real-world data have been brought by a study on the efficacy of lorlatinib in patients with non-small cell lung cancer (NSCLC) with a mutation in the ROS1 gene.
News COVID Pneumonia: How Can Erdosteine Help and What Did a Clinical Study Suggest?
When patients who have recovered from COVID pneumonia begin home treatment, they are often far from being symptom-free. General practitioners and outpatient pulmonologists often have to address these persistent symptoms. According to a study conducted by Recipharm, erdosteine may be a suitable adjunct treatment for these patients, even when they have negative COVID-19 tests. Why is this the case?
News Cognitive changes in MS – what can teriflunomide do?
In Phase III clinical trials, teriflunomide demonstrated its ability to slow down brain tissue atrophy in patients with relapsing-remitting multiple sclerosis (RRMS). What impact did the treatment have on the cognitive state of these patients?
News Impact of the COVID-19 Pandemic on People with Schizophrenia Spectrum Disorders
The COVID-19 pandemic has a far-reaching impact on the physical and mental health of the global population. The current situation poses an undue burden on patients suffering from schizophrenia as well as other psychiatric disorders. According to recent studies, individuals with schizophrenia spectrum disorders have higher mortality rates and worsening disease progression or overall quality of life.
News Prenatal Phenotype of Children with Noonan Syndrome
Until recently, the various phenotypes of RASopathies were clinically diagnosed only after birth. However, we are now striving for the earliest possible diagnosis, sometimes even prenatally. Ultrasound examination of the fetus during screening tests, focusing on certain characteristic morphological changes, plays a crucial role in this. In the case of pathological findings on imaging methods, molecular genetic testing and monitoring of pregnancy in specialized centers are indicated.
News Dynamics of Allergy Development in Children
The prevalence of allergic diseases in children in developed countries has been steadily increasing in recent decades. Slovak authors attempted to describe the dynamics of the development of allergic symptoms in a prospective cohort of children who developed atopic dermatitis, rhinoconjunctivitis, wheezing, urticaria, or food allergy within the first 5 years of life.
News From Hell to the Light at the End of the Tunnel – A Task for Eletriptan
In recent months, under the spotlight of new biological treatments, the focus has been predominantly on the prophylactic treatment of migraines. However, we should not forget about acute therapy. In this indication, the pharmacological group of triptans is dominant. So, does eletriptan reliably stop the hell named a migraine attack? And is the response to this drug consistent?
News FLEX – A New Predictive Model for Assessing Follicular Lymphoma Risks
Overall survival of patients with advanced-stage follicular lymphoma (FL) who experience early disease progression after chemotherapy remains low. Currently used clinical prognostic models do not provide optimal sensitivity and specificity for identifying this patient subgroup. The presented study by an international team of authors introduced a new assessment index that achieves better outcomes.
News Traveling with MS – Is Vaccination a Limitation?
What about the need for vaccination when traveling abroad? Which vaccines should you be cautious about? And how to time vaccination concerning disease activity and the individual medications used in multiple sclerosis (MS) therapy?
News Spectrum of Mechanisms of Action of Fenfluramine in the Treatment of Rare Epilepsies
Fenfluramine (FFA) is an anticonvulsant used in the treatment of rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. In addition to effectively reducing seizure frequency, it also mitigates non-seizure comorbidities in patients with these conditions. Last year, Belgian authors published a detailed review of all its described mechanisms of action. They also explain how these mechanisms might contribute to the clinical benefits of FFA beyond seizure suppression, such as reducing the risk of sudden unexpected death in epilepsy (SUDEP) or improving executive functions.
News Potential of Aloe to Reduce Severity of Symptoms in Patients with IBS − What Emerged from the Analysis of Fecal Microflora and Metabolite Profiles?
Current treatment options for irritable bowel syndrome (IBS − irritable bowel syndrome) are relatively limited. This increases interest in complementary and alternative therapy options with plant preparations. One modality used to alleviate IBS symptoms is Aloe barbadensis Mill. The aim of a clinical study by Swedish researchers was to assess the effect of aloe on IBS symptoms compared to a control treatment with inulin.
News What did the first data from the pilot lung cancer screening show?
Czech pulmonologists have released the first interim results of this year's pilot testing of heavy smokers due to the risk of lung cancer. More than 4,000 patients passed through the hands of general practitioners, and 900 subsequently underwent low-dose CT examination. What other specific findings emerge from the data collection? And what challenges do the experts involved in this program face?
News Subclinical Hypothyroidism Associated with the Use of Allopurinol? What the Results of a Large Multicenter Study Suggested
Allopurinol is a widely used drug for the treatment of hyperuricemia and gout. The retrospective study presented below investigated whether its long-term use is associated with an increased risk of developing subclinical hypothyroidism.
News Risk of Subsequent Fractures in Postmenopausal Women After Initial Fracture
Osteoporosis is associated with an increased risk of fractures. The prospective analysis presented below examined the risk of subsequent fractures in postmenopausal women after an initial fracture depending on its location.
News View on the Treatment of Rheumatoid Arthritis with Baricitinib Using the NNT Indicator
Clinical parameters assessed by patients themselves are an important tool in evaluating the effectiveness of new drugs and are particularly significant in the evaluation of treatments for chronic painful conditions, such as rheumatoid arthritis (RA). An analysis of clinical trial results presented at the European Rheumatology e-Congress in June 2020 focused on the effectiveness of the Janus kinase inhibitor baricitinib on parameters assessed directly by patients. Effectiveness was analyzed using the NNT indicator.
News Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL
Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In combination with bendamustine and rituximab (pola-BR), this drug is administered in the 3rd and subsequent lines of treatment for relapsed or refractory (R/R) DLBCL. If allogeneic hematopoietic stem cell transplantation (HSCT) is not feasible, patients with R/R DLBCL generally have a very poor prognosis, with limited further treatment options. However, at the 61st American Society of Hematology (ASH) congress held in December 2019 in Orlando, promising results were presented from extended follow-up of patients treated in clinical studies with the pola-BR combination.
News Impact of Lifestyle on the Benefit of Pharmacotherapy for Hypertension and Dyslipidemia
Antihypertensive and hypolipidemic therapy reduces the risk of cardiovascular (CV) diseases. Observational studies have shown that factors of a healthy lifestyle also have this influence. But is the benefit of pharmacotherapy for hypertension and dyslipidemia influenced by adherence to a healthy lifestyle? This question was attempted to be answered by an analysis of data from the clinical study HOPE-3.